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influence health-related quality of life（QOL）and 
increase anxiety and depression 5）.
Antimuscarinic drugs are the first-line treatment 
for OAB6,7）. However, these drugs frequently cause 
dry mouth, which cannot be relieved by drinking 
water because the latter aggravates the accompany-
ing urgency and pollakisuria 8,9）. Constipation, another 
potential side effect, can further aggravate OAB 
symptoms, thereby compromising patient adherence 
to therapy 10）. On the other hand, another therapeutic 
agent for OAB, namely, transdermal oxybutynin for-
mulation, is reported to reduce the generation of 
N-desethyloxybutynin（DEO）, which is the main 
cause of adverse reactions 11）. Therefore, we hypothe-
sized that the oxybutynin patch may induce fewer 
adverse reactions than existing oral antimuscarinic 
drugs.
INTRODUCTION
Overactive bladder（OAB）is a symptom syndrome 
that features urgency commonly accompanied by uri-
nary frequency, but not necessarily urgency inconti-
nence 1）. A European epidemiological survey found 
that the prevalence of OAB increases with age and 
that 16.6％ of persons aged 40 years or older have 
OAB2,3）. In Japan, OAB has been reported to affect 
12.4％ of the population over the age of 40 years 4）. A 
recent study showed that OAB symptoms negatively 
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SUMMARY
Objectives：To evaluate the efficacy and safety of once-daily oxybutynin patch for overactive bladder
（OAB）patients not tolerating oral antimuscarinic drugs. 
Methods：We prospectively investigated 43 OAB patients treated with once-daily oxybutynin patches 
for dry mouth and constipation due to oral antimuscarinic drugs. 
Results：Oxybutynin patch treatment for 8 weeks significantly improved the visual analogue scale 
scores for dry mouth and constipation；total score and subscore（mean number of urgency episodes and 
daily micturitions）for OAB symptoms；and King’s Health Questionnaire scores for social limitations, emo-
tions and sleep/energy（P＝0.016 and 0.001；0.008, 0.041 and 0.015；and 0.007, 0.003 and 0.026, respec-
tively）. The 3-day frequency volume chart showed significant improvement in hours of undisturbed sleep
（P＝0.011）. Eight patients had adverse reactions at the application site and withdrew from the study, 
while others only developed mild erythema and pruritus. 
Conclusions：Oxybutynin patch reduces adverse reactions caused by oral antimuscarinic drugs.
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We investigated the efficacy and safety of a once-
daily transdermal application of oxybutynin hydrochlo-
ride（oxybutynin patch）in Japanese OAB patients 
who developed adverse reactions, such as dry mouth 
or constipation, when treated with oral antimuscarinic 
drugs.
MATERIALS AND METHODS
This study was designed as a prospective investiga-
tion. The study protocol was approved by the Ethics 
Committee of Dokkyo Medical University Koshigaya 
Hospital, and this study was conducted in compliance 
with the Helsinki Declaration（1310）. We obtained 
written informed consent from all participants after 
thoroughly explaining the efficacy and possible 
adverse reactions of oxybutynin patch.
Patients who met all of the following criteria were 
enrolled in this study：（1）age 20 or more；（2）an 
average of 8 or more micturitions daily, with an aver-
age of one or more urgency or urgency incontinence 
episodes per day；（3）presence of OAB symptoms for 
at least 2 months；and（4）histoly of adverse reactions 
such as dry mouth or constipation when treated with 
oral antimuscarinic drugs. On the other hand, patients 
with a histoly of any of the following were excluded 
from the study：（1）urodynamic stress incontinence；
（2）other diseases causing symptoms difficult to differ-
entiate from those of OAB；（3）residual urine volume 
of 100 ml or more, and（4）a skin condition that could 
be exacerbated by the application of the drug patches 
investigated in this study.
The subjects had been receiving oral antimuscaric 
drugs until the day of enrollment in this study（day 
0）. On enrollment, they received 8 weeks of treatment 
with a once-daily oxybutynin patch（73.5 mg per 
35 cm2 patch）. The patch was applied on the lower 
abdomen, hip region, or thigh, and the site of applica-
tion was changed every day. If possible, the patches 
were changed at the same time of the day throughout 
the treatment period. Patients were asked to refrain 
from using other medications that influence urinary 
frequency and incontinence, drugs with anticholiner-
gic activity, and cholinergic agents during the study 
period.
The efficacy of treatment was assessed using the 
data collected from a questionnaire and 3-day fre-
quency volume chart（FVC）, both before and after 
the 8-week treatment period. The scores of the visual 
analogue scale（VAS）for dry mouth and constipation, 
OAB Symptom Score（OABSS）, and King’s Health 
Questionnaire（KHQ）were determined by a physician
（HY）who was blinded on the clinical background of 
the patients. The primary end-point was a change in 
the mean VAS scores of dry mouth and constipation. 
The secondary end-points were changes in the means 
of the following parameters：（1）urgency episodes 
per day,（2）urgency incontinence episodes per day,
（3）number of micturations per night, and（4）number 
of micturitions per day. The patient’s QOL was 
assessed on the basis of the domain scores of the 
KHQ.
Safety of the treatment was assessed in terms of 
the number and severity of adverse events, results of 
laboratory tests, values of vital parameters, and post-
void residual urine. Adverse events were investigated 
throughout the treatment period. Laboratory tests 
and measurement of vital signs were conducted 
before and the end of the 8-week period（or at dis-
continuation）. Further, postvoid residual urine was 
measured by abdominal ultrasonography before and 
at the end of 4 and 8 weeks of treatment（or at dis-
continuation）. The complete blood count was obtained, 
and blood chemistry tests were performed for the fol-
lowing parameters：serum levels of albumin, lactate 
dehydrogenase, alkaline phosphatase, aspartate amino-
transferase, alanine transaminase, total bilirubin, creat-
inine, urea nitrogen, sodium, potassium and chlorine. 
Urinalysis was performed at every visit.
Data are reported as means±SD and were ana-
lyzed using SPSS software version 12.0（IBM, Chicago, 
IL USA）. Wilcoxon signed-rank test was used to eval-
uate the effects of treatment, and P＜0.05 was consid-
ered significant.
RESULTS
Baseline Patient profile
In total, 43（17 men and 26 women）patients were 
recruited in the study. The study was completed by 
33（13 men and 20 women）patients：2 patients were 
excluded for not meeting all the inclusion criteria, 
while 8 were unable to continue the study because of 
adverse reactions at the site of patch application. The 
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baseline demographics and characteristics of the 33 
patients investigated are provided in Table 1.
Efficacy
The mean VAS scores for dry mouth and constipa-
tion were significantly improved after the 8-week 
treatment period（P＝0.016 and 0.001, respectively）
（Table 2）. The total scores and sub-scores of OABSS
（the mean number of urgency episodes and micturi-
tions per day）also showed significant improvement（P
＝0.008, 0.041 and 0.015, respectively）, while other 
OABSS sub-scores（the mean number of urge inconti-
nence episodes per day and micturations per night）
did not. The scores for the KHQ domains of social lim-
itations, emotions, and sleep/energy improved signifi-
cantly（P＝0.007 , 0 . 003 and 0 .026 , respectively）, 
whereas the others（role limitation, physical limitation, 
and personal relationship）did not show any such 
improvement. The FVC showed significant improve-
ment in the hours of undisturbed sleep（HUS；time 
between falling asleep and first waking to void）（P＝
0.011）, but not in the other parameters（nocturnal 
polyuria index, mean number of micturition per day, 
and nocturnal micturations per night）.
Safety
The results of blood biochemistry and urinalysis 
remained unchanged at 8 weeks（data not shown）. 
Application-site dermatitis occurred in 14（32.5％）of 
the 33 patients（5 men and 9 women）. Further, the 
Table 1　Clinical characteristics
n＝33
Age（years）
　Mean（SD） 74.7±6.2
　Range 67-80
Sex, n（％）
　Male 13（39.4）
　Female 20（60.6）
Weight（kg）
　Mean（SD） 56.3±9.2
　Range 39.2-88.3
Oral antimuscaric drugs, n（％）
　Solifenacin succinate 13（39.4）
　Tolterodine tartrate 9（27.3）
　Imidafenacine 8（24.2）
　Propiverine hydrochloride 3（9.1）
OABSS
　Total score 7.1±3.3
　Number of micturitions per day 0.7±0.6
　Number of nocturnal micturations per night 2.1±0.9
　Urgency episodes per day 2.6±1.7
　Urge incontinence episodes per day 1.6±1.6
UFM and FVC
　PVR（ml） 12.3±16.1
　Number of micturitions per day 9.6±2.1
　Number of micturations per night 2.5±1.1
　NPI 36.6±12.2
OABSS＝overactive bladder symptom score
UFM＝uroflowmetry
FVC＝freaquency volume chart
PVR＝post-void residual urine
NPI＝nocturnal polyuria index
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residual urine volume changed from 12.3±16.1 ml to 
15.9±33.4 ml, but the increase was not significant. 
The major skin symptoms observed among the 
patients were mild erythema and pruritus, and no 
severe symptoms were observed in any patient. We 
administered topical steroids and provided appropri-
ate care to the patients who discontinued treatment 
because of adverse events at the site of patch applica-
tion. The treatment administered led to successful 
resolution of the symptoms in all these patients.
DISCUSSION
Non-oral antimuscarinic drugs are associated with 
better patient adherence compared with oral ones 12）. 
In Europe and North America, antimuscarinic drugs 
are marketed in a variety of forms, including extend-
ed release, rectal suppository, transdermal patch, and 
gel preparations 13）. In Japan, however, only the oral 
form had been available for OAB until 2013；this lim-
ited the treatment options for patients who experi-
enced strong adverse reactions, such as dry mouth or 
constipation, when treated with oral antimuscarinic 
drugs. The beta 3-adrenoceptor agonist is reported to 
be free of these characteristic adverse reactions of 
antimuscarinic drugs 14）, but it has been launched into 
the market only recently and its safety profile in 
pharmacotherapy has not been clearly established. 
The present study was conducted to investigate the 
efficacy and safety of a new once-daily transdermal 
oxybutynin patch in Japanese patients. Transdermal 
formulations avoid a rapid increase in the blood con-
centration of oxybutynin, so stable levels are estab-
lished over a long period 11）. This formulation also 
reduces the generation of DEO, an active metabolite 
of oxybutynin, because transdermal delivery avoids 
the first-pass metabolism in the liver；therefore, it is 
Table 2　Change in parameters
Pretreatment After treatment for 8 weeks P-value
VAS score
　Dry mouth 4.8±2.3 3.6±2.4 0.016
　Constipation 3.0±3.1 1.2±2.3 0.001
OABSS
　Total 7.1±3.3 5.7±2.9 0.008
　Urgency episodes 2.6±1.7 2.0±1.5 0.041
　Urge incontinence 1.6±1.6 1.4±1.5 0.180
　Number of nocturnal micturations 2.1±0.9 1.9±0.9 0.100
　Number of micturitions 0.7±0.6 0.5±0.4 0.015
KHQ
　Role limitation 33.0±23.4 29.0±21.4 0.190
　Physical limitation 18.6±12.6 14.2±12.1 0.093
　Social limitation 10.5±9.4 5.2±8.6 0.007
　Personal relationship 17.5±13.9 14.2±13.5 0.068
　Emotions 29.1±16.7 19.3±12.8 0.003
　Sleep and energy 24.1±12.8 17.6±11.7 0.026
FVC
　Number of micturition 9.6±2.1 9.5±2.8 0.183
　Number of nocturia 2.5±1.1 2.4±1.2 0.171
　NPI 0.36±0.28 0.32±0.15 0.260
　HUS（hours） 2.6±1.4 4.0±1.5 0.021
VAS＝visual analogue scale
OABSS＝overactive bladder symptom score
KHQ＝King’s Health Questionnaire
FVC＝Frequency volume chart
NPI＝nocturnal polyuria index；ratio of nocturnal urine volume to 24 hour urine volume
HUS＝hours of undisturbed sleep；time between falling asleep and first waking to void
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expected to induce fewer adverse reactions than 
existing oral antimuscarinic drugs 11,15）. Assessment of 
this study using VAS scores for dry mouth and con-
stipation showed that this oxybutynin patch could 
induce fewer adverse reactions related to its antimus-
carinic effects.
An another transdermal oxybutynin formulation
（Oxytrol；Watson Pharmaceuticals, Corona, CA, 
USA）that contains 36 mg of oxybutynin is available 
in the USA and Europe. It is administered by a 
twice-weekly regimen（3- to 4-day dosing interval）, 
and 3.9 mg of oxybutynin is estimated to reach to the 
skin with 24-h application 16）. On the other hand, the 
oxybutynin patch is designed to obtain a stable plas-
ma concentration with application to a different skin 
site every day 15）. In a previous study, a single oxybu-
tynin patch was applied to the lower abdomen, lum-
ber region or thigh for 24-h, and it was found that 
5.1-6.8 mg of the active ingredient entered the skin 17）. 
In a multicenter, randomized, double-blind, placebo 
controlled study of transdermal oxybutynin adminis-
tered by a twice-weekly regimen, the mean decrease 
in the average daily frequency of urination showed no 
significant difference between the study group and 
the placebo group due to the high placebo response 18）. 
In contrast, in the clinical study of oxybutynin patch 
with the same design as the transdermal oxybutynin 
administered by a twice-weekly regimen, the mean 
number of micturitions per day showed a significant 
decrease in the oxybutynin patch group despite a 
high placebo response 17）. These results suggest that a 
stable and high plasma concentration of oxybutynin 
makes a contribution to the decrease of the number 
of micturitions per day.
Once-daily treatment with the oxybutynin patch 
also had a favorable influence on sleep quality. 
Although the mean number of nocturnal micturations 
showed no significant difference, significant improve-
ment was noted in the sleep/energy domain of the 
KHQ and HUS in FVC. HUS is considered an impor-
tant indicator of sleep quality and as a useful parame-
ter for evaluating sleep disorder caused by nocturia 19）. 
Sleep has two main phases：rapid eye movement
（REM）sleep and non-REM sleep 19）. Non-REM sleep 
normally makes up approximately three-quarters of 
the total sleeping time and is deep sleep that is impor-
tant for growth hormone secretion and functional res-
toration, whereas REM sleep is shallow and related to 
mental health 20）. Slow-wave sleep is a deep and 
restorative non-REM sleep that occurs within approx-
imately 3 to 4 hours of falling asleep, after which 
REM sleep and other shallow sleep stages become 
more prominent 20,21）. The interruption of this restor-
ative non-REM sleep can significantly impair sleep 
quality, causing fatigue and discomfort. Djavan et al. 
reported that prolonging early undisturbed sleep may 
be effective for improving sleep quality 22）. The results 
of the present analysis showed that the HUS was pro-
longed by an average of 84 min, which means that 
early sleep was also significantly prolonged. Prolonga-
tion of early sleep is thought to have a positive influ-
ence on sleep quality and is reflected by the improve-
ment of the sleep/energy domain in the KHQ.
In the present study, the incidence of adverse 
events at the site of patch application was 32.5％, and 
due to these adverse events, 18.6％ of the participants 
exited the study, but none of the patients developed 
any severe adverse events. In general, adverse events 
at the application site due to transdermal oxybutynin 
formulation were reported in 26-40％, and discontinu-
ation due to these adverse events were noted in 5-10
％20,21）. These adverse events are probably caused by 
skin stimulation by oxybutynin, but typically, they 
manifested as erythema or pruritus and resolved 
quickly without intervention or with the administra-
tion of topical formulations 21,23）. The reason for a high-
er incidence of adverse events and subsequent exit of 
patients from this study is unclear. However, Yamagu-
chi et al. attributed the adverse effects of the events 
the oxybutynin patch observed in Japanese patients 
to racial differences of cutaneous sensitivity to oxybu-
tynin and the hot, humid Japanese climate 20,23）.
The limitations of this study were the small sample 
size, lack of a placebo group, and the omission of uro-
dynamic data. Future research in the form of prospec-
tive, randomized, controlled trial of once-daily admin-
istration of the oxybutynin patch in OAB patients 
experiencing adverse reactions to oral antimuscarinic 
drugs would be required to confirm the finding of this 
study.
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CONCLUSIONS
The results of the present analysis showed that 
once-daily administration of the oxybutynin patch 
alleviates the adverse reactions caused by oral anti-
muscarinic drugs besides prolonging HUS, which is an 
indicator of sleep quality. Therefore, we recommend 
the use of the oxybutynin patch in patients with OAB 
experiencing adverse effects of oral antimuscarinic 
drugs and sleep disturbances.
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